Today: 8 June 2026
Browse Category

AMS:WKL 5 December 2025 - 4 February 2026

Wall Street futures steady after AI shock; Alphabet earnings and jobs data in focus

Wall Street futures steady after AI shock; Alphabet earnings and jobs data in focus

Dow futures rose 0.16% premarket, S&P 500 futures edged up 0.04%, and Nasdaq 100 futures dipped 0.06% after Tuesday’s tech-led selloff. The S&P 500 closed down 0.84%, Nasdaq fell 1.43%, and Dow lost 0.34% as AI disruption concerns hit software stocks. Chipmaker AMD warned of weaker revenue, sending shares down 8% after hours. President Trump signed a bill ending a four-day partial government shutdown.
4 February 2026
·········
Stock market today: Nasdaq falls on artificial intelligence fears as Palantir pops and Walmart hits $1 trillion

Stock market today: Nasdaq falls on artificial intelligence fears as Palantir pops and Walmart hits $1 trillion

The S&P 500 fell 1.3% and the Nasdaq dropped nearly 2% Tuesday, erasing early gains, while the Dow slipped 0.9%. Palantir shares rose after an upbeat revenue forecast, but Microsoft and other major tech stocks declined. A partial U.S. government shutdown delayed key economic reports. Investors await Alphabet and Amazon earnings later this week.
3 February 2026
············
2025 Gartner Magic Quadrant for Financial Planning Software: Workday, OneStream and Board Front an AI Arms Race in FP&A

2025 Gartner Magic Quadrant for Financial Planning Software: Workday, OneStream and Board Front an AI Arms Race in FP&A

Gartner released its 2025 Magic Quadrant for Financial Planning Software, evaluating 14 vendors including Workday, OneStream, and Board. Within hours, several vendors announced new leadership roles and AI-driven strategies. Workday reported its fourth consecutive year as a Leader, highlighting its focus on agentic AI and unified enterprise planning. Announcements followed December 4–5, 2025.
5 December 2025
········

Stock Market Today

  • Ashok Leyland Shares Drop Over 31% Amid US-Iran Conflict and Economic Challenges
    June 8, 2026, 9:05 AM EDT. Ashok Leyland shares have fallen more than 31% since the start of the US-Iran conflict, erasing about Rs 38,656 crore from the truck maker's market capitalization. Nomura flagged that macroeconomic headwinds such as rising fuel prices, inflation, and potential interest rate hikes could pressure India's economic growth. The medium and heavy commercial vehicle segment, where Ashok Leyland operates, is especially vulnerable to economic slowdowns, adding to investor concerns amid geopolitical tensions.

Latest articles

Plug Power Stock Faces a Make-or-Break Week After Friday’s 10% Drop

Plug Power Stock Faces a Make-or-Break Week After Friday’s 10% Drop

8 June 2026
Plug Power rose 2.95% to $3.31 in Monday pre-market trading after a $39.2 million federal tax credit sale tied to its St. Gabriel hydrogen facility, as investors await CEO Jose Luis Crespo’s June 11 update on liquidity and asset sales amid ongoing losses and a recent 10.69% stock drop.
ABAT Shares Jump on DOE’s $115M Lithium Grant Return

ABAT Shares Jump on DOE’s $115M Lithium Grant Return

8 June 2026
American Battery Technology Co shares soared 29.58% to $4.03 premarket after the U.S. Department of Energy fully reinstated a $115 million grant for its Nevada lithium refinery, restoring federal funding for the Tonopah Flats Lithium Project with no change to awarded funds or milestones, though risks remain from permitting, financing, and volatile lithium prices.
NANO Nuclear Stock Bounces, Investors Eye What’s Next

NANO Nuclear Stock Bounces, Investors Eye What’s Next

8 June 2026
NANO Nuclear Energy jumped 7.8% to $25.40 in premarket trading after a 9.9% Friday drop, as traders weighed fresh insider sales filings and recent regulatory progress on its KRONOS microreactor project; the company held $568.7 million in cash as of March 31, but faces sector-wide volatility and execution risks.
Nurix Shares Jump Premarket on Roche $2.3 Billion Cancer Drug Deal

Nurix Shares Jump Premarket on Roche $2.3 Billion Cancer Drug Deal

8 June 2026
Nurix soared 20.4% to $17.62 premarket after Roche agreed to pay $700 million up front in a bexobrutideg collaboration worth up to $2.3 billion, a major cash boost and external validation for Nurix’s lead blood cancer drug ahead of a planned Phase 3 trial, with Roche’s clinical and commercial backing now in play.
Go toTop